ABI, BG Medicine, FDA, Invitrogen, Illumina, Beckman Coulter, Eksigent | GenomeWeb
ABI’s Mass Spec Tools to Play Role in BG, FDA Hepatotoxicity Biomarker Project
 
The US Food and Drug Administration has approved the first phase of a BG Medicine and National Center for Toxicological Research project to develop biomarkers for liver toxicity, BG Medicine said this week.
 
The company also said it will use mass spectrometry technology made by Applied Biosystems, and has named seven pharmaceutical companies that will participate in the project.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."